Who Owns Novelion Therapeutics Company?

Novelion Therapeutics Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Holds the Reins of Novelion Therapeutics Now?

The story of Novelion Therapeutics is a compelling case study in the volatile world of biopharmaceuticals. From its inception to its eventual acquisition, understanding the shifting sands of Novelion ownership is key to grasping its strategic journey. Unraveling the ownership structure reveals critical insights into its financial health and operational decisions.

Novelion Therapeutics, initially known as QLT Inc., navigated a challenging landscape, ultimately leading to its acquisition after a bankruptcy filing. This Novelion Therapeutics SWOT Analysis can help you understand the company's strengths and weaknesses during this period. Exploring the evolution of Novelion ownership, including its parent company and major shareholders, provides a crucial understanding of the company's trajectory and its ultimate fate. The question of "Who owns Novelion" is central to understanding its current status and future prospects, including whether it is publicly traded or if Novelion Therapeutics has been acquired.

The story of Novelion Therapeutics begins with its origins as QLT Inc., established in 1981. While the exact details of the founders and their initial ownership stakes are not readily available in the provided information, the early structure of QLT laid the groundwork for Novelion's future.

A significant shift in the company's ownership occurred with the merger of QLT Inc. and Aegerion Pharmaceuticals, Inc. This strategic move reshaped the shareholder landscape and set the stage for Novelion's evolution.

Understanding the early ownership of Novelion Therapeutics is crucial for grasping its corporate journey and the influence of key stakeholders. The merger between QLT and Aegerion significantly altered the company's ownership structure.

The pivotal merger between QLT Inc. and Aegerion Pharmaceuticals, Inc., finalized on November 29, 2016, marked a turning point. QLT acquired Aegerion, and the combined entity was renamed Novelion Therapeutics Inc. This acquisition had a direct impact on the ownership distribution.

Ownership Structure Post-Merger

Following the merger, the pre-merger shareholders of QLT held approximately 68% of the outstanding common shares of the newly formed Novelion. The pre-merger stockholders of Aegerion owned about 32%. This transaction effectively made Aegerion an indirect wholly-owned subsidiary of Novelion.

• The merger was a strategic move to combine the strengths of both companies.
• The transaction was structured to provide Novelion with additional capital for future operations.
• The merger significantly altered the ownership distribution, with QLT shareholders maintaining a majority stake.
• The acquisition of Aegerion by QLT, which later became Novelion Therapeutics, is a key part of the Marketing Strategy of Novelion Therapeutics.

Novelion Therapeutics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of Novelion Therapeutics underwent significant shifts following its formation. Initially, the merger of QLT Inc. and Aegerion Pharmaceuticals in November 2016 established a structure where QLT shareholders held approximately 68% and Aegerion stockholders held around 32% of Novelion's common shares. However, financial difficulties and legal issues, particularly concerning Aegerion's marketing practices, led to substantial changes in its ownership profile.

Aegerion Pharmaceuticals, a wholly-owned subsidiary of Novelion, filed for Chapter 11 bankruptcy on May 20, 2019. This event was a pivotal moment, triggering a recapitalization plan that involved Amryt Pharma Plc acquiring 100% of Aegerion's reorganized stock. This acquisition effectively converted Novelion's assets into Amryt shares, significantly altering the company's ownership and its future trajectory. To learn more, you can read the Brief History of Novelion Therapeutics.

Before the acquisition by Amryt Pharma, key Novelion investors included EdgePoint Investment Group Inc., which held approximately 12.1% of outstanding common shares, and Broadfin Capital, LLC, with about 10.9%. The acquisition by Amryt Pharma fundamentally changed the ownership structure, as Novelion's assets were primarily converted into Amryt shares. This shift highlights the dynamic nature of corporate ownership, especially during periods of financial distress and strategic restructuring. The bankruptcy of Aegerion and subsequent acquisition by Amryt Pharma were critical events that redefined the ownership of Novelion Therapeutics.

Key Takeaways on Novelion Ownership

Novelion Therapeutics' ownership structure has evolved significantly due to strategic acquisitions and financial challenges.

• The merger of QLT Inc. and Aegerion Pharmaceuticals initially shaped the ownership.
• Bankruptcy and acquisition by Amryt Pharma led to major shifts in ownership.
• Major shareholders like EdgePoint Investment Group and Broadfin Capital were significant before the acquisition.
• The acquisition by Amryt Pharma altered the ownership significantly.

Novelion Therapeutics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

At the time leading up to its bankruptcy and subsequent acquisition, the board of directors of Novelion Therapeutics played a critical role. The board approved strategic transactions that reshaped its ownership. The new secured financing by Aegerion in late 2018 was unanimously approved by Novelion's board, all of whom were independent.

The composition of the board and its influence were central to the company's trajectory. However, specific details about the board members and their affiliations during the final stages of Novelion's independent operation are not fully available. The board's decisions were crucial in navigating the financial challenges that ultimately led to the acquisition.

The voting structure of Novelion Therapeutics, as of September 13, 2019, required a quorum for annual meetings to be not less than 33 1/3% of the issued and outstanding common shares. Shareholders were entitled to vote on various proposals, including liquidation and liquidator resolutions. This structure highlights the importance of shareholder voting power in critical decisions. The company's liquidation plan, which included the distribution of any remaining property to shareholders, was subject to shareholder approval.

Shareholder Voting Power

Shareholders had significant voting power in decisions regarding liquidation and the disposition of company assets. The voting structure required a quorum of at least 33 1/3% of outstanding shares for annual meetings.

• Shareholders voted on liquidation and liquidator resolutions.
• Whitefort Capital Master Fund, LP sought a special meeting for voting.
• The liquidation plan required shareholder approval.
• One-share-one-vote structure suggests equal voting rights.

Novelion Therapeutics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The most significant recent development for Novelion Therapeutics involves its effective dissolution and the subsequent acquisition of its core assets. Following a bankruptcy filing in 2019, Amryt Pharma Plc acquired 100% of Aegerion Pharmaceuticals, Inc., Novelion's operating subsidiary. This deal gave Amryt control over Aegerion's commercial drugs, Juxtapid and Myalept. These drugs had generated $136.5 million in sales in 2018. After the acquisition, Novelion Therapeutics entered a voluntary liquidation process, which began on January 16, 2020. As part of this liquidation, Novelion distributed American Depositary Receipts (ADRs) representing approximately 14.0 million ordinary shares of Amryt to its shareholders. The company officially ceased to operate independently on March 10, 2023.

The initial acquisition by Amryt Pharma set the stage for further ownership changes. Amryt Pharma was itself acquired by Chiesi Farmaceutici S.p.A. on April 12, 2023. Chiesi acquired Amryt Pharma Plc for around $1.25 billion, with potential additional payments. This acquisition expanded Chiesi's rare disease portfolio, including the products originally held by Aegerion. This reflects a trend of larger pharmaceutical companies acquiring specialized rare disease companies to enhance their portfolios. For more information on Novelion Therapeutics and its strategic direction, you can read this article: Growth Strategy of Novelion Therapeutics.

The rare disease market was valued at approximately $230 billion in 2024 and is expected to reach $350 billion by 2028. This demonstrates the ongoing interest in this sector.

Who Owns Novelion Now?

Novelion Therapeutics no longer exists as an independent entity. Its assets were acquired, and the company entered liquidation. The core assets, including drugs like Juxtapid and Myalept, are now part of Chiesi Farmaceutici S.p.A.'s portfolio.

What Happened to Novelion Investors?

Novelion investors received shares of Amryt Pharma as part of the liquidation process. These shares were later impacted by Amryt's acquisition by Chiesi. The final distribution of remaining Amryt ADRs and cash was completed before the company's statutory dissolution.

The Current Status of Novelion

Novelion Therapeutics officially ceased operations on March 10, 2023. Its former assets and operations are now integrated within other pharmaceutical companies, primarily Chiesi Farmaceutici S.p.A.

Future of the Rare Disease Market

The rare disease market is experiencing significant growth, with an estimated value of $230 billion in 2024 and projected to reach $350 billion by 2028. This growth is driven by increasing investments in research and development.

Novelion Therapeutics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs